Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

BACKGROUND: Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash with vem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Rathod, Akash D., Rowland, Andrew, Kichenadasse, Ganessan, Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045585/
https://www.ncbi.nlm.nih.gov/pubmed/32103736
http://dx.doi.org/10.1186/s12885-020-6659-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045585/
https://www.ncbi.nlm.nih.gov/pubmed/32103736
http://dx.doi.org/10.1186/s12885-020-6659-0

Ejemplares similares